LadRx Corp financial data

Symbol
LADX on OTC
Industry
Biological Products, (No Diagnostic Substances)
Location
11726 San Vicente Boulevard, Suite 650, Los Angeles, CA
State of incorporation
Delaware
Fiscal year end
December 31
Former names
CYTRX CORP (to 9/23/2022)
Latest financial report
10-Q - Q2 2024 - Aug 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 104 % -5.98%
Return On Equity -5.76K % -65338%
Return On Assets -328 % -24340%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 495K shares 0%
Common Stock, Shares, Outstanding 495K shares 0%
Entity Public Float 1.1M USD -72.5%
Common Stock, Value, Issued 495 USD 0%
Weighted Average Number of Shares Outstanding, Basic 495K shares +1.37%
Weighted Average Number of Shares Outstanding, Diluted 495K shares +1.37%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 594K USD
General and Administrative Expense 2.93M USD -30.2%
Operating Income (Loss) -3.85M USD +8.78%
Nonoperating Income (Expense) 1.42K USD
Net Income (Loss) Attributable to Parent -6.97M USD -19041%
Earnings Per Share, Basic -7.95 USD/shares -192%
Earnings Per Share, Diluted -7.95 USD/shares -140%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 817K USD -77.3%
Cash, Cash Equivalents, and Short-term Investments 800K USD
Assets, Current 889K USD -76.8%
Property, Plant and Equipment, Net 3.25K USD -74.3%
Operating Lease, Right-of-Use Asset 31.6K USD -85.4%
Other Assets, Noncurrent 1.48K USD -80.9%
Assets 894K USD -77.6%
Accounts Payable, Current 833K USD -20.7%
Employee-related Liabilities, Current 157K USD -22.7%
Liabilities, Current 1.83M USD -17%
Operating Lease, Liability, Noncurrent 33.5K USD -84.5%
Liabilities 2.2M USD -0.92%
Retained Earnings (Accumulated Deficit) -490M USD -0.57%
Stockholders' Equity Attributable to Parent -934K USD -152%
Liabilities and Equity 894K USD -77.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -5.88M USD -741%
Net Cash Provided by (Used in) Financing Activities -68.8K USD +66.6%
Common Stock, Shares Authorized 62.4M shares 0%
Common Stock, Shares, Issued 495K shares 0%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -5.88K USD +99.2%
Deferred Tax Assets, Valuation Allowance 105M USD -6.05%
Deferred Tax Assets, Gross 105M USD -6.05%
Operating Lease, Liability 33.6K USD -85.4%
Payments to Acquire Property, Plant, and Equipment 766 USD
Lessee, Operating Lease, Liability, to be Paid 33.7K USD -85.6%
Property, Plant and Equipment, Gross 48.7K USD 0%
Operating Lease, Liability, Current 33.6K USD -82.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 33.7K USD -83.2%
Lessee, Operating Lease, Liability, to be Paid, Year One 33.7K USD -83.2%
Operating Lease, Weighted Average Discount Rate, Percent 0.04 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 67 USD -98.7%
Deferred Tax Assets, Operating Loss Carryforwards 74.8M USD -0.2%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 833K shares 0%
Additional Paid in Capital 489M USD +0.01%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 2.06K USD -30.4%
Deferred Tax Assets, Net of Valuation Allowance 105K USD -6.05%
Share-based Payment Arrangement, Expense 51.1K USD
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%